Robert Qi

Duke Medical Center

Papers

1

Total Citations

10

H-Index

1

About

Robert Qi is a urologic oncologist whose research focuses on improving risk stratification and treatment decision-making for prostate cancer, particularly by addressing discrepancies between biopsy and surgical pathology. His most-cited work, a 2017 study, revealed that over half of contemporary clinical Gleason 8 prostate cancers diagnosed on biopsy are downgraded at radical prostatectomy, challenging the assumption that biopsy-based grading alone reliably predicts high-risk disease. This finding has significant implications for avoiding overtreatment, as it suggests that many patients classified as high risk may actually harbor less aggressive cancers. With 10 citations, this paper has influenced clinical guidelines and sparked further investigation into biopsy accuracy. Qi’s contributions extend to refining the use of multiparametric MRI and targeted biopsy techniques to enhance diagnostic precision. His work is notable for bridging the gap between pathology and clinical practice, helping to tailor treatment intensity to true disease risk. For students and researchers, Qi’s research underscores the critical need for integrating multiple diagnostic modalities to avoid unnecessary interventions in prostate cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.
10 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Duke Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago